Table 2 De novo inhibitors occurring in... | American Society of Hematology

Table 2

De novo inhibitors occurring in previously treated patients with hemophilia A who switched from plasma-derived to recombinant FVIII during prospective licensure studies

Recombinant product	No. of patients	No. of de novo inhibitors
Recombinate (full-length)⁴³	69	0
Kogenate (full-length)⁴⁴	86	1
Kogenate-FS (full-length)⁴⁵	73	0
Refacto (B-domainless)⁴⁶	113	1
Advate (full-length)⁴⁷	108	1
Refacto (B-domainless)⁴⁸	204	3

Recombinant product	No. of patients	No. of de novo inhibitors
Recombinate (full-length)⁴³	69	0
Kogenate (full-length)⁴⁴	86	1
Kogenate-FS (full-length)⁴⁵	73	0
Refacto (B-domainless)⁴⁶	113	1
Advate (full-length)⁴⁷	108	1
Refacto (B-domainless)⁴⁸	204	3

View Large

This Feature Is Available To Subscribers Only